Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jul;116(7):1920-1929.
doi: 10.1111/cas.70086. Epub 2025 Apr 22.

Pyrotinib and Nab-Paclitaxel in HER2-Positive Breast Cancer (PANHER Trial): A Prospective, Single-Arm, Phase II Trial

Huan Li  1 , Min Yan  2 , Zhaohui Li  3 , Xiujie Cui  4 , Xuening Ji  5 , Fengqi Fang  6 , Yuyang Zhang  7 , Yan Wang  1 , Xiangyu Guo  1 , Mingxi Jing  1 , Zhichao Gao  1 , Hui Cao  1 , Fangyuan Dong  1 , Jie Wu  1 , Cui Jiang  1 , Yangyang Duan  1 , Xiaorui Li  1 , Yujun Jiang  1 , Lei Jiang  1 , Ying E  1 , Yufeng Jia  1 , Liang Zhang  1 , Pai Peng  8 , Tao Sun  1
Affiliations
Clinical Trial

Pyrotinib and Nab-Paclitaxel in HER2-Positive Breast Cancer (PANHER Trial): A Prospective, Single-Arm, Phase II Trial

Huan Li et al. Cancer Sci. 2025 Jul.

Abstract

Trastuzumab and pertuzumab combined with chemotherapy represent the standard therapy for first-line treatment of HER2-positive metastatic breast cancer (BC). Due to challenges related to availability and cost in China, it is necessary to explore treatments involving tyrosine kinase inhibitors (TKIs). In this multicenter, single-arm, open-label phase II trial, patients with HER2-positive BC were enrolled from seven hospitals in China. Patients received oral pyrotinib 400 mg once daily and intravenous nab-paclitaxel 125 mg/m2 on days 1, 8, and 15 of each 28-day cycle until disease progression or intolerable toxicity. The primary endpoint was the objective response rate (ORR). Between December 2019 and December 2021, 51 patients were enrolled. Among all enrolled patients, 48 had at least one response evaluation. Of these evaluable patients, 39 patients achieved responses, resulting in a positive study outcome. The ORR was 76.5% (95% CI, 62.5%-87.2%), and the disease control rate was 94.1% (95% CI, 83.8-98.8). As of January 24, 2024, the median follow-up duration was 29.2 months (IQR, 24.9-33.2). The median progression-free survival was 14.6 months (95% CI, 8.0-24.2), and the median overall survival was not reached. Forty-nine patients (96.1%) developed grade ≥ 3 adverse events (AEs). The most common grade ≥ 3 AEs were decreased neutrophil count (43.1%), decreased white blood cell count (43.1%), and diarrhea (23.5%). Pyrotinib combined with nab-paclitaxel demonstrated promising efficacy for HER2-positive advanced breast cancer, with an acceptable safety profile. Trial Registration: chictr.org, ChiCTR1900023653.

Keywords: HER2; breast cancer; nab‐paclitaxel; pyrotinib; tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

Pai Peng is an employee in Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Figures

FIGURE 1
FIGURE 1
Patients flow.
FIGURE 2
FIGURE 2
Best change from baseline.
FIGURE 3
FIGURE 3
Kaplan‐Meier plot for overall survival (A) and progression‐free survival (B) in the full analysis set.
FIGURE 4
FIGURE 4
Subgroup analysis for progression‐free survival.
See this image and copyright information in PMC

References

    1. Slamon D. J., Godolphin W., Jones L. A., et al., “Studies of the HER‐2/Neu Proto‐Oncogene in Human Breast and Ovarian Cancer,” Science 244, no. 4905 (1989): 707–712, 10.1126/science.2470152. - DOI - PubMed
    1. Slamon D. J., Leyland‐Jones B., Shak S., et al., “Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer That Overexpresses HER2,” New England Journal of Medicine 344 (2001): 783–792, 10.1056/nejm200103153441101. - DOI - PubMed
    1. Marty M., Cognetti F., Maraninchi D., et al., “Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2‐Positive Metastatic Breast Cancer Administered as First‐Line Treatment: The M77001 Study Group,” Journal of Clinical Oncology 23, no. 19 (2005): 4265–4274, 10.1200/jco.2005.04.173. - DOI - PubMed
    1. Swain S. M., Miles D., Kim S. B., et al., “Pertuzumab, Trastuzumab, and Docetaxel for HER2‐Positive Metastatic Breast Cancer (CLEOPATRA): End‐Of‐Study Results From a Double‐Blind, Randomised, Placebo‐Controlled, Phase 3 Study,” Lancet Oncology 21, no. 4 (2020): 519–530, 10.1016/s1470-2045(19)30863-0. - DOI - PubMed
    1. Montemurro F., Donadio M., Clavarezza M., et al., “Outcome of Patients With HER2‐Positive Advanced Breast Cancer Progressing During Trastuzumab‐Based Therapy,” Oncologist 11 (2006): 318–324, 10.1634/theoncologist.11-4-318. - DOI - PubMed

Publication types

MeSH terms